Drug intelligence / Profile preview

levofloxacin + metronidazole

Development stage
Unknown
Lead developer
Daiichi Sankyo
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

Levofloxacin + metronidazole is a fixed-dose combination of two antibiotics used primarily to treat mixed infections involving both aerobic and anaerobic bacteria, such as diarrhea, dysentery, intra-abdominal infections, and as part of second-line therapy for Helicobacter pylori eradication. Levofloxacin is a fluoroquinolone antibiotic that acts by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and cell division in bacteria. This results in bactericidal activity against a broad spectrum of Gram-positive and Gram-negative organisms. Metronidazole is an antimicrobial agent effective against anaerobic bacteria and certain parasites; it works by damaging microbial DNA through the formation of toxic metabolites under anaerobic conditions. The combination provides synergistic coverage for polymicrobial infections where both aerobic (e.g., Escherichia coli) and anaerobic (e.g., Bacteroides fragilis) pathogens are present[1][2][5][8].

02

Targets

DNA gyraseTopo IV (Bacterial Topoisomerase IV)Neuraminidase

Beyond the preview

Go deeper on levofloxacin + metronidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on levofloxacin + metronidazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call